Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Former Philadelphia Eagles quarterback Rodney Peete joined Sumitomo Pharma America’s Time to Go campaign. 1 The promotional ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

Stand Up To Cancer returns on August 15. The biennial fundraising event is scheduled to occur in Nashville this year, which ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

The new platform integrates PCR-based diagnostic data with statistical modeling and AI to provide real-time visibility into ...

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...